<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2420">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129657</url>
  </required_header>
  <id_info>
    <org_study_id>CSD201001</org_study_id>
    <nct_id>NCT05129657</nct_id>
  </id_info>
  <brief_title>CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches</brief_title>
  <official_title>An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Three P10 Nicotine Pouches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-site, open-label, randomized, 5-way cross-over study designed to evaluate&#xD;
      elements of abuse liability (AL) including subjective effects and physiological measures&#xD;
      (pharmacodynamics [PD]) and plasma nicotine uptake (pharmacokinetics [PK]) during and&#xD;
      following ad libitum use of the study investigational products (IPs) by generally healthy&#xD;
      smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smokers and smokers also using smokeless tobacco products (ST) will be recruited&#xD;
      into this AL study to evaluate elements of AL of three nicotine pouches compared to&#xD;
      combustible cigarettes (CC) and nicotine polacrilex gum. At least one-third of the study&#xD;
      population will include smokers who also use ST.&#xD;
&#xD;
      Potential subjects may complete a pre-screening telephone interview. Subjects will complete a&#xD;
      Screening Visit to assess their eligibility within 45 days prior to check-in and enrollment.&#xD;
&#xD;
      Starting on Day 1, subjects will check-in at the clinical site to complete procedures to&#xD;
      confirm eligibility. Eligible subjects will be enrolled and confined for 6 days. Subjects&#xD;
      will be randomized to one of 10 product use sequences (using a Williams Design) in which the&#xD;
      subjects will evaluate one IP in each of five separate Test Sessions, such that each subject&#xD;
      will evaluate five IPs, including three IPs, and both a high-AL comparator (subject's usual&#xD;
      brand [UB] cigarette) and a low-AL comparator (a commercially available nicotine replacement&#xD;
      therapy [NRT] nicotine gum).&#xD;
&#xD;
      On Day 2 and continuing through Day 6, subjects will participate in Test Sessions that will&#xD;
      last for approximately 4 hours. Each Test Session will include collection of both PD measures&#xD;
      (subjective and physiological) and PK measures prior to, during, and following IP use.&#xD;
&#xD;
      On the half day prior to each respective Test Session, a Product Acclimation Period will&#xD;
      allow subjects ad libitum use of the randomized IP (at least two trial uses) for product&#xD;
      familiarization prior to use in the next day's Test Session. Subjects can also use their UB&#xD;
      cigarettes ad libitum, until the 12-hour tobacco abstinence begins prior to each Test&#xD;
      Session, as long as the minimum use requirement for randomized IP is met.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 23, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUECPL) 5-240: area-under-the-effects curve (AUEC) for Product Liking (PL)</measure>
    <time_frame>5 minutes to 240 minutes</time_frame>
    <description>area-under-the-effects curve (AUEC) for PL numeric rating scale (NRS) score-versus-time curve from 5 minutes to 240 minutes after the start of IP use. Product Liking is a numeric rating scale ranging from 0 to 10. A higher score indicates a higher liking of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax PL: Maximum product liking (PL)</measure>
    <time_frame>240 minutes</time_frame>
    <description>Maximum product liking (PL) numeric rating scale (NRS) score after the start of IP use. Product Liking is a numeric rating scale ranging from 0 to 10. A higher score indicates a higher liking of the product.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (ABCDN) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (ACBND) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (BADCN) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (BDANC) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (CANBD) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (CNADB) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (DBNAC) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (DNBCA) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (NCDAB) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (NDCBA) during an evaluation period, followed by a 4 hour Test Session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>Usual Brand (UB) filtered, non-menthol or menthol cigarette</description>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>P1012914, A nicotine pouch product with 4 mg of nicotine</description>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>P1012915, A nicotine pouch product with 8 mg of nicotine</description>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>P1012919, A nicotine pouch product with 12 mg of nicotine</description>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product N</intervention_name>
    <description>Nicorette® White Ice Mint 4 mg nicotine gum</description>
    <arm_group_label>Product usage order ABCDN</arm_group_label>
    <arm_group_label>Product usage order ACBND</arm_group_label>
    <arm_group_label>Product usage order BADCN</arm_group_label>
    <arm_group_label>Product usage order BDANC</arm_group_label>
    <arm_group_label>Product usage order CANBD</arm_group_label>
    <arm_group_label>Product usage order CNADB</arm_group_label>
    <arm_group_label>Product usage order DBNAC</arm_group_label>
    <arm_group_label>Product usage order DNBCA</arm_group_label>
    <arm_group_label>Product usage order NCDAB</arm_group_label>
    <arm_group_label>Product usage order NDCBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in&#xD;
             length as primary source of tobacco.&#xD;
&#xD;
          4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for&#xD;
             at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit&#xD;
             attempt (prior to 30 days of Screening), or clinical study participation (prior to 30&#xD;
             days of Screening) will be allowed at the discretion of the PI.&#xD;
&#xD;
          5. Smokers who also use ST products (e.g., moist snuff, snus), and have used ST within 30&#xD;
             days prior to screening, will be enrolled.&#xD;
&#xD;
          6. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is&#xD;
             defined as the reported cigarette brand and style currently smoked most frequently by&#xD;
             the subject.&#xD;
&#xD;
          7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and&#xD;
             at check-in Day 1.&#xD;
&#xD;
          8. Positive urine cotinine test at Screening.&#xD;
&#xD;
          9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1&#xD;
             (&quot;How soon after you wake up do you smoke your first cigarette?&quot;) is either &quot;Within 5&#xD;
             minutes&quot; or &quot;6-30 minutes&quot; (Heatherton et al., 1991).&#xD;
&#xD;
         10. Willing to use the UB cigarette, IPs, and Nicorette® nicotine gum during the study&#xD;
             period.&#xD;
&#xD;
         11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the&#xD;
             start of each of five Test Sessions.&#xD;
&#xD;
         12. Females must be willing to use a form of contraception acceptable to the PI from the&#xD;
             time of signing the informed consent until End-of-Study.&#xD;
&#xD;
             Examples of acceptable means of birth control are, but not limited to:&#xD;
&#xD;
               1. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion,&#xD;
                  bilateral oophorectomy, bilateral salpingectomy);&#xD;
&#xD;
               2. physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with&#xD;
                  spermicide;&#xD;
&#xD;
               3. non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g.,&#xD;
                  Mirena or Kyleena);&#xD;
&#xD;
               4. vasectomized partner; and&#xD;
&#xD;
               5. post-menopausal and not on hormone replacement therapy.&#xD;
&#xD;
         13. Agrees to an in-clinic confinement of 6 days (5 nights).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             the PI, makes the study subject unsuitable to participate in this clinical study.&#xD;
&#xD;
          2. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          3. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the Screening Visit. As-needed treatment, such as inhalers, may be included&#xD;
             at the PI's discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          4. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
          5. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          6. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95 mmHg,&#xD;
             measured after being seated for five minutes at Screening and at check-in Day 1.&#xD;
&#xD;
          7. Weight of ≤ 110 pounds.&#xD;
&#xD;
          8. Hemoglobin level is &lt; 12.5 g/dL for females or &lt; 13.0 for males g/dL at Screening.&#xD;
&#xD;
          9. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
         10. A positive urine drug screen without evidence of prescribed corresponding concomitant&#xD;
             medication(s) at Screening or check-in Day 1.&#xD;
&#xD;
         11. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         12. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®),&#xD;
             bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to&#xD;
             signing the informed consent.&#xD;
&#xD;
         13. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or self-reports a previous quit attempt within (≤) 30&#xD;
             days prior to signing the informed consent.&#xD;
&#xD;
         14. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.&#xD;
&#xD;
         15. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         16. Whole blood donation within 8 weeks (≤ 56 days) prior to signing the informed consent&#xD;
             and between Screening and check-in Day 1.&#xD;
&#xD;
         17. Plasma donation within (≤) 7 days prior to signing the informed consent and between&#xD;
             Screening and check-in Day 1.&#xD;
&#xD;
         18. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         19. Participation in another clinical trial within (≤) 30 days prior to signing the&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing the informed consent&#xD;
             in the current study.&#xD;
&#xD;
         20. Drinks more than 21 servings of alcoholic beverages per week.&#xD;
&#xD;
         21. Has a positive alcohol result at Screening or check-in Day 1.&#xD;
&#xD;
         22. Determined by the PI to be inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milly Kanobe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RAIS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Prevette</last_name>
    <phone>336-741-1873</phone>
    <email>prevetk1@rjrt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elite Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

